<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>DY-9760e (3-[2-[4-(3-chloro-2-<z:chebi fb="0" ids="52553">methylphenyl</z:chebi>)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-<z:chebi fb="0" ids="36669,36671">indazole</z:chebi> dihydrochloride 3.5 hydrate), a novel calmodulin <z:chebi fb="68" ids="48706">antagonist</z:chebi>, provides effective protection against Ca(2+) <z:chebi fb="0" ids="24869">ionophore</z:chebi>-induced cytotoxicity and brain injury induced by transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we evaluated the effect of DY-9760e on ischemic <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in rats subjected to permanent focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>DY-9760e (0.5 mg/kg/h for 6 h) significantly reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume when administered immediately after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, this neuroprotection was also exerted by treatment with a 3-hour delay, implying that the therapeutic time window for this compound is at least 3 h </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, although treatment with 0.1 mg/kg/h for 24 h was ineffective, the combination of a loading dose of 0.3 mg/kg/h for 2 h followed by 0.1 mg/kg/h for 22 h yielded a significant reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, prolonged infusion preceded by a loading dose is an efficacious dosing regimen for DY-9760e, especially at a low infusion rate </plain></SENT>
<SENT sid="6" pm="."><plain>These data demonstrate the substantial neuroprotective effect of DY-9760e in a permanent focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> model and indicate that this neuroprotectant may be of therapeutic value for the treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>